Steven Keith Burke Akebia Therapeutics, Inc. (AKBA) insider trading activity

Steven Keith Burke is SVP, Chief Medical Officer of Akebia Therapeutics, Inc.. Currently has a direct ownership of 816,234 shares of AKBA, which is worth approximately $1.7 Million. The most recent transaction as insider was on Feb 03, 2025, when has been sold 50,506 shares (Common Stock) at a price of $2.1 per share, resulting in proceeds of $106,062. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 816K

17.3% 3M change

14.74% 12M change

Total Value Held $1.7 Million

Steven Keith Burke Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Feb 03 2025	SELL Open market or private sale	$106,062 $2.1 p/Share	50,506 Reduced 5.83%	816,234 Common Stock
Jan 31 2025	BUY Grant, award, or other acquisition	-	194,900 Added 18.36%	866,740 Common Stock
Feb 29 2024	SELL Open market or private sale	$11,327 $1.58 p/Share	7,169 Reduced 1.02%	695,840 Common Stock
Feb 27 2024	SELL Open market or private sale	$12,717 $1.52 p/Share	8,367 Reduced 1.18%	703,009 Common Stock
Feb 01 2024	SELL Open market or private sale	$40,842 $1.68 p/Share	24,311 Reduced 3.3%	711,376 Common Stock
Jan 31 2024	BUY Grant, award, or other acquisition	-	202,200 Added 21.56%	735,687 Common Stock
Aug 25 2023	SELL Open market or private sale	$31,049 $1.15 p/Share	27,000 Reduced 3.88%	668,840 Common Stock
May 16 2023	SELL Open market or private sale	$68,016 $1.07 p/Share	63,567 Reduced 10.7%	530,487 Common Stock
Mar 01 2023	SELL Open market or private sale	$12,428 $0.88 p/Share	14,123 Reduced 2.32%	594,054 Common Stock
Feb 27 2023	SELL Open market or private sale	$6,106 $0.81 p/Share	7,539 Reduced 1.22%	608,177 Common Stock
Jan 31 2023	BUY Grant, award, or other acquisition	-	196,200 Added 24.17%	615,716 Common Stock
Aug 31 2022	SELL Open market or private sale	$413 $0.36 p/Share	1,147 Reduced 0.27%	418,016 Common Stock
May 12 2022	BUY Grant, award, or other acquisition	-	200,000 Added 32.38%	417,663 Common Stock
Mar 01 2022	SELL Open market or private sale	$16,614 $2.17 p/Share	7,656 Reduced 3.4%	217,663 Common Stock
Feb 28 2022	SELL Open market or private sale	$15,910 $2.15 p/Share	7,400 Reduced 4.32%	163,819 Common Stock
Feb 28 2022	BUY Grant, award, or other acquisition	-	60,000 Added 21.14%	223,819 Common Stock
Aug 31 2021	SELL Open market or private sale	$2,949 $2.83 p/Share	1,042 Reduced 0.6%	171,219 Common Stock
Apr 01 2021	SELL Open market or private sale	$3,675 $3.4 p/Share	1,081 Reduced 0.63%	170,761 Common Stock
Mar 16 2021	BUY Grant, award, or other acquisition	-	10,400 Added 5.71%	171,842 Common Stock
Mar 01 2021	SELL Open market or private sale	$25,697 $3.4 p/Share	7,558 Reduced 4.47%	161,442 Common Stock
Feb 26 2021	BUY Grant, award, or other acquisition	-	70,000 Added 29.29%	169,000 Common Stock

SKB

Steven Keith Burke

SVP, Chief Medical Officer

Cambridge, MA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells AKBA shares.

Notify only if

Value

Insider Trading

Get notified when an Akebia Therapeutics, Inc. insider buys or sells AKBA shares.

Notify only if

Operation

Value

Type

News

Receive news related to Akebia Therapeutics, Inc.

Track Activities on AKBA

Account